asa foetida (HAB) D4, crataegus e fructibus recentibus D4, lycopus virginicus (HAB) D3, passiflora incarnata (HAB) D4 - αποτελεσματα

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

rasagiline mylan

mylan pharmaceuticals limited - rasagiliin tartraat - parkinsoni tõbi - parkinsoni tõve ravimid - rasagiliini mylan on näidustatud idiopaatilise parkinsoni tõve (pd) raviks monoteraapiana (ilma levodopa) või lisaravimina (koos levodopaga) patsientidel, kel ravimiannus.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

rasagiline ratiopharm

teva b.v. - rasagiliin - parkinsoni tõbi - parkinsoni tõve ravimid - rasagiliini ratiopharm on näidustatud idiopaatilise parkinsoni tõve (pd) raviks monoteraapiana (ilma levodopa) või lisaravimina (koos levodopaga) patsientidel, kel ravimiannus.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

dasatinib accord

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Ευρωπαϊκή Ένωση - Εσθονικά - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatiniib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastilised ained - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.